avatar for Eric Crombez

Eric Crombez

Ultragenyx Gene Therapy
Chief Medical Officer
Dr. Crombez has extensive experience and expertise in the development and execution of clinical development programs for rare genetic disorders. He currently serves as chief medical officer, Ultragenyx Gene Therapy and Inborn Errors of Metabolism. He has held this position since Ultragenyx, a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases using multiple treatment modalities including adeno-associated virus (AAV) gene delivery technology, acquired Dimension Therapeutics, a liver-directed AAV gene therapy company, in November 2017. Dr. Crombez joined Dimension Therapeutics as chief medical officer in November 2014. While there, he led clinical development efforts for four clinical-stage programs including gene therapy programs for hemophilia B, hemophilia A (in partnership with Bayer), ornithine transcarbamylase (OTC) deficiency and glycogen storage disorder type Ia (GSDIa). Currently, Dr. Crombez serves as an industry representative on the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee.

Prior to his work in gene therapy, Dr. Crombez held positions at Shire in its Human Genetics Therapy business unit for nearly 8 years. He most recently served as senior medical director of Global Clinical Development, playing a key role in advancing pivotal trials and global marketing registration submissions for VPRIV, an enzyme replacement therapy for the treatment of Type 1 Gaucher disease that is now available in the United States and more than 40 other countries. Dr. Crombez also served as the physician lead for Shire’s enzyme replacement therapy for Fabry disease and the clinical development lead for a partnership with Amicus Therapeutics to develop chaperone therapy for several rare diseases. Dr. Crombez also played a key role in advancing Shire’s intrathecal enzyme replacement therapy program for metachromatic leukodystrophy from bench research into clinical trials.

Prior to joining the biopharma industry, Dr. Crombez was an assistant professor in the Department of Pediatrics, Division of Medical Genetics, at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).

Dr. Crombez has authored more than 40 peer-reviewed articles, book chapters and presentation abstracts. He earned a B.S. in biology from the University of Michigan, Ann Arbor, and an M.D. from Wayne State University School of Medicine. He completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at UCLA School of Medicine. He is a board-certified clinical geneticist.
  • Timezone
  • Filter By Type
  • Executive Interview
  • Keynote
  • Networking Break
  • Panel Session
  • Virtual Happy Hour